PDF factsheet
      Z

ALK inhibitors in lung cancer (metastatic) for ALK positive patients, clinical trials results

alectinib versus chemotherapy
ALUR, 2018
NCT02604342
oral alectinib at a dose of 600 milligrams (mg) twice daily
versus
chemotherapy with either pemetrexed (500 milligrams per square meter [mg/m^2] of body surface area) or docetaxel (75 mg/m^2) intravenously.
ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib
alectinib versus crizotinib
ALEX, 2017
NCT02075840
alectinib 600 mg orally (four 150 mg capsules) BID
versus
Crizotinib
patients with stage IIIB or IV, ALK-positive NSCLC who had not received prior systemic therapy open label
USA
ceritinib versus chemotherapy
ASCEND-4, 2017
NCT01828099
oral ceritinib 750 mg/day
versus
platinum-based chemotherapy ([cisplatin 75 mg/m2 or carboplatin AUC 5-6 plus pemetrexed 500 mg/m2] every 3 weeks for four cycles followed by maintenance pemetrexed
untreated patients with stage IIIB/IV ALK-rearranged non-squamous NSCLC open-label
ceritinib versus pemetrexed or docetaxel
ASCEND 5, 2017
NCT01828112
Oral LDK378 750 mg once daily
versus
pemetrexed or docetaxel
patients previously treated with chemotherapy (platinum doublet) and crizotinib
USA
crizotinib versus chemotherapy
Shaw, 2013
NCT00932893
crizotinib (250 mg) twice daily
versus
intravenous chemotherapy with either pemetrexed (500 mg per square meter of body-surface area) or docetaxel (75 mg per square meter) every 3 weeks
patients with locally advanced or metastatic ALK-positive lung cancer who had received one prior platinum-based regimenopen-label
PROFILE 1014, 2014
NCT01154140
oral crizotinib, at a dose of 250 mg twice daily
versus
Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin
patients with advanced ALK-positive nonsquamous NSCLC who had received no previous systemic treatment for advanced diseaseopen-label
Follow-up duration: 16.7 months

  Options


in first

in second

  Filter